Adicet Bio Overview

  • Founded
  • 2014

Founded
  • Status
  • Public

  • Employees
  • 94

Employees
  • Stock Symbol
  • ACET

Stock Symbol
  • Investments
  • 2

  • Share Price
  • $17.77

  • (As of Tuesday Closing)

Adicet Bio General Information

Description

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 200 Clarendon Street
  • Floor 6
  • Menlo Park, CA 94025
  • United States
+1 (650) 000-0000

Adicet Bio Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Adicet Bio Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$17.77 $16.70 $9.54 - $21.87 $716M 42.9M 570K -$1.45

Adicet Bio Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 330,981 512,923 167,671
Revenue 30,458 9,730 17,903 995
EBITDA (55,397) (60,501) (38,918) (27,819)
Net Income (55,728) (61,999) (36,678) (28,138)
Total Assets 354,303 338,938 153,835 81,587
Total Debt 21,717 20,944 21,639 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Adicet Bio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Adicet Bio‘s full profile, request access.

Request a free trial

Adicet Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Adicet Bio‘s full profile, request access.

Request a free trial

Adicet Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therap
Drug Discovery
Menlo Park, CA
94 As of 2022
00000
00000000 00000

0000 0

ation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderi
0000 000000000
Cambridge, MA
00 As of 0000
00000
00000000 00000

000000

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatu
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Adicet Bio Competitors (34)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aura Biosciences Formerly VC-backed Cambridge, MA 00 00000 00000000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
0000000 Venture Capital-Backed Philadelphia, PA 00 00000 00000000000 00000
0000 000000000000 Formerly VC-backed South San Francisco, CA 00 00000 000000000 00000
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
You’re viewing 5 of 34 competitors. Get the full list »

Adicet Bio Patents

Adicet Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220372439-A1 Methods for selective expansion of gamma delta t-cell populations and compositions thereof Pending 11-Apr-2022 0000000000
AU-2020398623-A1 Methods for expanding γδ t-cell populations with multivalent agents and compositions thereof Pending 03-Dec-2019 0000000000
EP-4072567-A2 Methods for expanding gamma delta t-cell populations with multivalent agents and compositions thereof Pending 03-Dec-2019 0000000000
CA-3160609-A1 Methods for expanding gamma delta t-cell populations with multivalent agents and compositions thereof Pending 03-Dec-2019 0000000000
CA-3126896-A1 Methods for selective in vivo expansion of .gamma. .delta. t-cell populations and compositions thereof Pending 03-Dec-2018 A61K35/17
To view Adicet Bio’s complete patent history, request access »

Adicet Bio Executive Team (14)

Name Title Board Seat Contact Info
Chen Schor Chief Executive Officer & Board Member
Nick Harvey Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Don Healey Ph.D Chief Technology Officer, Technology
Blake Aftab Ph.D Chief Scientific Officer
Francesco Galimi MD Chief Medical Officer
You’re viewing 5 of 14 executive team members. Get the full list »

Adicet Bio Board Members (13)

Name Representing Role Since
Andrew Sinclair Ph.D Self Board Member 000 0000
Aya Jakobovits Ph.D Adicet Bio Board Member 000 0000
Bastiano Sanna Ph.D Self Board Member 000 0000
Carl Gordon Ph.D Self Board Member 000 0000
Chen Schor Adicet Bio Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Adicet Bio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Adicet Bio Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Adicet Bio‘s full profile, request access.

Request a free trial

Adicet Bio Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 15-Sep-2020 0000000000 0000 Biotechnology 0000 0000
Applied Immune Technologies 27-Jan-2016 Merger/Acquisition Drug Discovery 000 00000
To view Adicet Bio’s complete acquisitions history, request access »